DMOA-derived mixed-element terpenoids in deep-sea fungi as well as preparation method, composition and application of DMOA-derived mixed-element terpenoids

The problem of existing anti-COVID-19 drugs is solved by extracting mixed terpenes from the deep-sea fungus Penicillium pancosmium A6A, and a significant anti-SARS-CoV-2 trVLP pseudovirus activity is achieved, providing new drugs The research and development direction has promoted the development of deep-sea biological resources.

CN118978502AInactive Publication Date: 2024-11-19THIRD INSTITUTE OF OCEANOGRAPHY STATE OCEANI C ADMINISTRATION
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202411060714.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There are currently no effective anti-COVID-19 drugs, and the high repetition rate of secondary metabolites on land microbials has led to a bottleneck in the development of new drugs. It is necessary to find active secondary metabolites against the new coronavirus from deep-sea fungi.

Method used

Mixed terpenes from DMOA-derived terpenes were extracted from the deep-sea fungus Penicillium pancosmium A6A, separated by ultrasonic extraction and column chromatography, and combined with high-pressure liquid chromatography, compounds with significant anti-SARS-CoV-2 trVLP pseudovirus activity were prepared. And combined with drug excipients.

Benefits of technology

Compounds 1 and 2 show significant antiviral activity, with IC50 values ​​of 22.37 and 18.12μM, respectively, providing candidate compounds for anti-CoV drugs, providing scientific basis for the development and utilization of deep-sea biological resources.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978502A_ABST
    Figure CN118978502A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of marine drugs. The invention specifically relates to a DMOA-sourced mixed-element terpenoid compound in deep-sea fungi, and a preparation method, a composition and an application thereof. The terpenoid is novel in structure, has remarkable antiviral activity in resisting SARS-CoV-2trVLP pseudovirus activity, and can be used for research and development of drugs for resisting new coronavirus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of marine drugs, and specifically relates to DMOA-derived mixed terpenoid compounds in deep-sea fungi, and a preparation method, a composition and an application thereof. Background Art

[0002] There is currently no safe and effective drug for the treatment of COVID-19. Therefore, it is urgent to develop potent and broad-spectrum anti-SARS-CoV-2 drugs.

[0003] Natural products have structural diversity and a wide range of biological activities, and are an important source of innovative drug research and development. Since the discovery of penicillin in the 1950s, terrestrial microorganisms have been concentrated in research and development. Today, the re-discovery rate of secondary metabolites of terrestrial microorganisms has reached 95%, which has become a bottleneck for the development of new drugs. Therefore, people have gradually turned their attention to the ocean, which has been less studied, especially the deep sea. The ocean accounts for about 71% of the earth's surface area, of which more than 90% is deep sea, which contains rich microbial resources.

[0004] Deep-sea fungi live in extreme marine environments and have gradually evolved unique metabolic regulation pathways that are different from terrestrial fungi. They may produce some secondary metabolites with novel structures and significant activities, thus providing model structures or lead compounds for the development of new drugs. In recent years, with the development of deep-sea sample collection and fungal isolation and culture technology, coupled with the advantages of rich fungal secondary metabolites and renewable resources, deep-sea fungi have become a hot area in natural product research. At present, my country's research and development of deep-sea biological resources started late and lags far behind developed countries. Therefore, it is of great strategic significance for my country to conduct research on active secondary metabolites of deep-sea fungi. Therefore, finding and discovering active secondary metabolites against the new coronavirus from deep-sea fungi is of great significance for the development of anti-COVID-19 drugs. Summary of the invention

[0005] The present invention provides a DMSO-derived mixed terpene compound, which is extracted from deep-sea fungus Penicillium pancosmium, preferably Penicillium pancosmium A6A, and has significant antiviral activity in anti-SARS-CoV-2 trVLP pseudovirus activity, and can be used for the development of anti-new coronavirus drugs. Specifically, the terpene compound provided by the present invention has one of the following structures or its stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts, prodrugs or isotope labels:

[0006]

[0007] The present invention also provides a pharmaceutical composition, comprising the terpene compound of the present invention and pharmaceutical excipients.

[0008] In some embodiments of the pharmaceutical composition, the pharmaceutical composition further comprises other active ingredients; the other active ingredients are traditional Chinese medicine ingredients and / or western medicine ingredients.

[0009] In some embodiments of the pharmaceutical composition, the western medicine ingredients include: at least one of apimod, R 82913, DS-6930, ONO 5334, oseltamivir phosphate, tetrandrine, clofazimine, astemizole, recombinant human angiotensin-converting enzyme 2 or favipiravir and / or pharmaceutically acceptable salts thereof.

[0010] The present invention also provides the use of the terpene compounds or the pharmaceutical composition described in the present invention in the preparation of drugs for preventing or treating diseases related to novel coronavirus infection.

[0011] In some embodiments of the described uses, it is characterized in that the new coronavirus is a SARS-CoV-2 trVLP pseudovirus.

[0012] The present invention also provides a method for preparing and extracting the terpenoid compound of the present invention, comprising:

[0013] (I) using an organic solvent to ultrasonically extract the fermentation product of the deep-sea fungus Penicillium pancosmiumA6A to obtain an organic extract; the organic solvent is selected from one or more combinations of dichloromethane, ethyl acetate, n-butanol, acetone, and methanol;

[0014] (II) separating the organic extract in step (I) by normal phase silica gel column chromatography, using a dichloromethane-methanol gradient elution system, first eluting with dichloromethane-methanol in a volume ratio of 1:0, then eluting with dichloromethane-methanol in a volume ratio of 1:1, and finally eluting with dichloromethane-methanol in a volume ratio of 0:1, each volume elution is 1 L, and three fractions Fr.1, Fr.2, and Fr.3 are obtained by combining;

[0015] (III) the fraction Fr.2 obtained in step (II) is first separated by a normal phase silica gel column, and then separated by a reverse ODS column and high pressure liquid chromatography to prepare compound 1;

[0016] (IV) The fraction Fr.3 obtained in step (II) is firstly separated by a reverse ODS column and then by a normal phase silica gel column and high pressure liquid chromatography to obtain compound 2.

[0017] In some embodiments of the method, the deep-sea fungus Penicillium pancosmium is Penicillium pancosmium A6A; preferably, Penicillium pancosmium A6A is a rice solid fermentation culture thereof.

[0018] In some embodiments of the methods, the fermentation culture comprises:

[0019] (1) The deep-sea fungus Penicillium pancosmium A6A activated on the PDA plate was inoculated into the PDB liquid culture medium, and the Erlenmeyer flask was placed in a shaker for shaking culture to prepare the seed culture medium;

[0020] (2) The seed culture solution in step (1) is expanded and inoculated into a rice culture medium, and placed in a 25° C. incubator for constant temperature static fermentation for 32 days.

[0021] Terminology

[0022] Certain embodiments of the present invention are now described in detail. The present invention is intended to cover all substitutions, modifications and equivalent technical solutions, which are all included in the scope of the present invention as defined in the claims. It should be appreciated by those skilled in the art that many methods and materials similar or equivalent to those described herein can be used to practice the present invention. The present invention is by no means limited to the methods and materials described herein. In the event that one or more of the combined documents, patents and similar materials are different from or contradictory to the present application (including but not limited to defined terms, term applications, described technologies, etc.), the present application shall prevail.

[0023] It should be further appreciated that certain features of the invention, which for clarity are described in multiple separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which for brevity are described in a single embodiment, may also be provided separately or in any suitable sub-combination.

[0024] Unless otherwise specified, all technical terms used in the present invention have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. All patents and publications related to the present invention are incorporated herein by reference in their entirety.

[0025] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "example", "specific example", or "some examples" etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representations of the above terms do not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner. In addition, those skilled in the art may combine and combine the different embodiments or examples described in this specification and the features of the different embodiments or examples, without contradiction.

[0026] In the following, all numbers disclosed herein are approximate, regardless of whether the words "about" or "approximately" are used. The value of each number may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15% or 20%. Whenever a number having a value of N is disclosed, any number having a value of N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, N+ / -10%, N+ / -15% or N+ / -20% is explicitly disclosed, where "+ / -" means plus or minus.

[0027] The term "comprising" is an open expression, that is, including the contents specified in the present invention but not excluding other contents.

[0028] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.

[0029] The term "tautomer" or "tautomeric form" refers to structural isomers with different energies that can be mutually converted through a low energy barrier. If tautomerism is possible (such as in solution), a chemical equilibrium of tautomers can be reached. For example, proton tautomers (protontautomers) (also known as prototropic tautomers) include mutual conversions by proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers include mutual conversions by the reorganization of some bonding electrons. A specific example of keto-enol tautomerism is the interconversion of pentane-2,4-dione and 4-hydroxypent-3-ene-2-one tautomers. Another example of tautomerism is phenol-keto tautomerism. A specific example of phenol-keto tautomerism is the interconversion of pyridine-4-ol and pyridine-4 (1H)-one tautomers. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.

[0030] The term "stereoisomers" refers to compounds that have identical chemical constitution, but differ in the way the atoms or groups are arranged in space. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotamers), geometric isomers (cis / trans isomers), atropisomers, and the like.

[0031] The term "nitrogen oxide" refers to when a compound contains several amine functional groups, one or more nitrogen atoms can be oxidized to form an N-oxide. A special example of an N-oxide is an N-oxide of a tertiary amine or an N-oxide of a nitrogen-containing heterocyclic nitrogen atom. The corresponding amine can be treated with an oxidizing agent such as hydrogen peroxide or a peracid (e.g., peroxycarboxylic acid) to form an N-oxide (see Advanced Organic Chemistry, Wiley Interscience, 4th edition, Jerry March, pages). In particular, N-oxides can be prepared by the method of LW Deady (Syn. Comm. 1977, 7, 509-514), wherein, for example, in an inert solvent such as dichloromethane, an amine compound is reacted with meta-chloroperbenzoic acid (MCPBA).

[0032] The term "metabolite" refers to a product obtained by the metabolism of a specific compound or its salt in vivo. The metabolite of a compound can be identified by techniques known in the art, and its activity can be characterized by experimental methods as described in the present invention. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, amidation, deamidation, esterification, defatting, enzymatic cleavage, etc. Accordingly, the present invention includes metabolites of compounds, including metabolites produced by contacting the compounds of the present invention with mammals for a period of time.

[0033] The term "pharmaceutically acceptable salt" refers to organic and inorganic salts of the compounds of the present invention. Pharmaceutically acceptable salts are well known in the art, as described in the literature: SM Berge et al., J. Pharmaceutical Sciences, 66: 1-19, 1977. Pharmaceutically acceptable salts include salts formed by compounds with acids, including but not limited to inorganic acid salts (such as hydrochlorides, hydrobromides, phosphates, sulfates, nitrates, perchlorates) and organic acid salts (such as acetates, glycolates, oxalates, maleates, tartrates, citrates, succinates, fumarates, mandelates, sulfosalicylate), or other methods described in books and literature, such as ion exchange methods, to obtain these salts. More pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, cyclopentylpropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oleate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, stearate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Pharmaceutically acceptable salts also include salts of compounds formed with bases, including, but not limited to, inorganic base salts (such as alkali metal salts, alkaline earth metal salts, ammonium salts and N+(C 1-4The present invention also contemplates quaternary ammonium salts formed by any compound containing N groups. Water-soluble or oil-soluble or dispersible products can be obtained by quaternization. Pharmaceutically acceptable salts further include appropriate, non-toxic ammonium, quaternary ammonium salts and amine cations formed by counter-balancing ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1-8 sulfonates and aromatic sulfonates. Organic base salts (such as primary amine salts, secondary amine salts and tertiary amine salts, substituted amines (including naturally occurring substituted amines, cyclic amines, basic ion exchange resins) salts), certain organic amine salts include, for example, isopropylamine salts, benzathine salts, choline salts, diethanolamine salts, diethylamine salts, lysine salts, meglumine salts, piperazine salts and tromethamine salts.

[0034] The term "solvate" refers to an association formed by one or more solvent molecules and the compound of the present invention. The solvent can be water, acetic acid, ether, isopropyl ether, petroleum ether, ethyl formate, ethyl acetate, isopropyl acetate, n-propyl acetate, isobutyl acetate, n-butyl acetate, methyl tert-butyl ether (MTBE), n-heptane, a mixed solvent of ethanol and water in a volume ratio of 10:90 to 90:10, acetone, methyl isobutyl ketone, acetonitrile, benzene, chloroform, carbon tetrachloride, dichloromethane, dimethyl sulfoxide, 1,4-dioxane, ethanol, ethyl acetate, ethylene glycol, n-butanol, tert-butanol , sec-butyl alcohol, N,N-dimethylacetamide, N,N-dimethylformamide, formamide, formic acid, n-hexane, cyclohexane, n-heptane, a mixed solvent of n-heptane and ethyl acetate in a volume ratio of 1:5 to 5:1, isopropanol, methanol, butanone, l-methyl-2-pyrrolidone, mesitylene, nitromethane, polyethylene glycol, n-propanol, isopropanol, 2-acetone, 4-methyl-2-pentanone, pyridine, tetrahydrofuran, methyl ethyl ketone, toluene, xylene, isopropylbenzene or a mixture thereof, etc.

[0035] The term "isotopically labeled" means that the compounds of the present invention are labeled with an isotope. They are identical to those described herein except for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Exemplary isotopes that may also be incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as 2 H, 3 H, 13 C, 14 C, 15 N, 16 Oh, 17 Oh, 31 P, 32 P, 36 S,18 F and 37 Cl.

[0036] The term "prodrug" as used in the present invention refers to a compound that is converted into the compound 1 or 2 of the present invention in vivo. Such conversion is affected by the hydrolysis of the prodrug in the blood or the conversion of the prodrug into the parent structure by enzymes in the blood or tissues. The prodrug compound of the present invention can be an ester. In the present invention, the esters that can be used as prodrugs include phenyl esters, aliphatic (C 1-24 ) esters, acyloxymethyl esters, carbonates, carbamates and amino acid esters. For example, a compound of the present invention contains a hydroxyl group, which can be acylated to obtain a compound in the form of a prodrug. Other prodrug forms include phosphate esters, such as these phosphate ester compounds obtained by phosphorylation of the hydroxyl group on the parent. For a complete discussion of prodrugs, please refer to the following documents: Higuchi et al., Pro-drugs as Novel Delivery Systems, Vol. 14, ACSSymposium Series; Roche et al., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987; Rautio et al., Prodrugs: Design and Clinical Applications, Nature Reviews Drug Discovery, 2008, 7, 255-270, and Hecker et al., Prodrugs of Phosphates and Phosphonates, J. Med. Chem., 2008, 51, 2328-2345.

[0037] The deep-sea fungus Penicillium pancosmium A6A of the present invention is deposited in the China Marine Microbiological Culture Collection Center, with the culture collection number: MCCC 3A00965, which can be shared through the culture collection number. The website for obtaining it is: https: / / www.mccc.org.cn / BacteriaService / Service1

[0038] Advantages of the present invention:

[0039] The present invention provides the use of DMOA-derived mixed terpenoid compounds or pharmaceutically acceptable salts thereof shown in compounds 1 and 2 in the preparation of anti-new coronavirus drugs. By evaluating the anti-SARS-CoV-2 trVLP pseudovirus activity of new structure compounds 1 and 2, it was found that both compounds 1 and 2 have significant antiviral activity, and their IC 50 The values ​​are 22.37 and 18.12 μM respectively, which can be used in the development of anti-new coronavirus drugs.

[0040] The present invention prepares a novel DMOA-derived mixed terpenoid compound from the solid fermentation product of rice of the deep-sea fungus Penicillium pancosmium A6A. The extraction and separation method is simple, and the strain can be repeatedly fermented to obtain raw materials. The mixed terpenoid compound has significant anti-new coronavirus pseudovirus activity. The present invention provides candidate compounds for the research and development of anti-new coronavirus drugs, provides a scientific basis for the development and utilization of deep-sea biological resources, and has good application development prospects. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 COSY, HMBC, and NOESY correlations of compound 1.

[0042] Figure 2 Experimental and quantum chemical calculations of ECD data for compound 1.

[0043] Figure 3 COSY, HMBC, and NOESY correlations of compound 2.

[0044] Figure 4 Experimental and quantum chemical ECD data were calculated for compound 2. DETAILED DESCRIPTION

[0045] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with embodiments. The specific embodiments described herein are only used to explain the present invention and are not intended to constitute any limitation of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concepts of the present disclosure. Such structures and technologies are also described in many publications.

[0046] The reagents used in the present invention can be purchased from the market or prepared by the method described in the present invention.

[0047] Example 1: Preparation and structural identification of DMOA-derived mixed terpenoid compounds involved in the present invention

[0048] 1. Preparation of new structure mixed terpenoid compounds derived from DMOA

[0049] (1) Preparation of seed culture solution of deep-sea fungus Penicillium pancosmium A6A: The fungus preserved in a -80°C glycerol tube (the present invention uses Penicillium pancosmium A6A, which can be obtained through commercial channels. The deep-sea fungus Penicillium pancosmium A6A of the present invention is deposited in the China Marine Microbiological Culture Collection Center, with a culture collection number of MCCC 3A00965, which can be shared through the culture collection number, and the website for obtaining it is: https: / / www.mccc.org.cn / BacteriaService / Service1) is inoculated into a PDA plate and placed in a 28°C biochemical incubator for 3 days. Then, in a clean bench, fresh mycelium and spores are inoculated into 100 mL of liquid PDB medium (100 mL of PDB in a 250 mL Erlenmeyer flask, autoclaved at 121°C for 25 min), and the inoculated Erlenmeyer flask is placed in a 25°C shaker (180 rpm) for 3 days to prepare a seed culture solution.

[0050] (2) Large-scale fermentation of deep-sea fungi Penicillium pancosmium A6A: The large-scale fermentation medium uses rice solid culture medium. Its formula is as follows: 100g rice, 4.9g sea salt, and 150mL tap water are placed in each 1L triangular flask. The seed culture solution is inoculated into the sterilized rice solid culture medium at a 1% inoculation rate, and a total of 40 1L triangular flasks are fermented and cultured. After inoculation, the triangular flasks are placed in a 25°C incubator for constant temperature static fermentation for 32 days.

[0051] (3) Extraction of large-scale fermentation products: After static fermentation, an equal volume of organic solvent was added, and then the cells were crushed and ultrasonically extracted in an ultrasonic cleaner for 10 min. Each bottle of fermentation culture was extracted three times, and then concentrated under reduced pressure by a rotary evaporator to obtain 9.2 g of fermentation extract.

[0052] (4) The ethyl acetate fermentation extract obtained in step (3) was subjected to normal phase silica gel column chromatography with a dichloromethane-methanol gradient elution system (1:0, 1:1, 0:1, v / v). After TLC analysis, three fractions (Fr.1, Fr.2, and Fr.3) were obtained by merging.

[0053] (5) The Fr.2 fraction obtained in step (4) was further subjected to normal phase silica gel column chromatography, and 8 fractions (SFr.2-1, SFr.2-2, SFr.2-3, SFr.2-4, SFr.2-5, SFr.2-6, SFr.2-7, SFr.2-8) were obtained by gradient elution with petroleum ether-ethyl acetate (1:0→0:1). Among them, SFr.2-5 was further subjected to reverse phase ODS column chromatography, and gradient elution with methanol-water (20% to 100%) was performed, and three fractions SFr.2-5-1 to SFr.2-5-3 were obtained after merging. Among them, the SFr.2-5-2 fraction was finally subjected to semi-preparative high pressure liquid chromatography (Cosmosil column, ODS-A, 5μm, 250×10mm), and acetonitrile-water was used as the mobile phase for elution (27:23) to obtain monomer compound 1 (20.2 mg).

[0054] (6) The Fr.3 fraction obtained in step (4) was separated by reverse phase ODS column chromatography, eluted with methanol-water gradient (15% to 100%), and three fractions SFr.3-1 to SFr.3-3 were obtained after TLC analysis and merging. The SFr.3-2 fraction was further separated by normal phase silica gel column chromatography, eluted isocratically with petroleum ether-ethyl acetate (15:1), and finally semi-preparative high pressure liquid chromatography (Cosmosil column, ODS-A, 5μm, 250×10mm) was used to elute with acetonitrile-water (11:9) as the mobile phase to obtain monomer compound 2 (4.9 mg).

[0055] 2. Structural identification of new structure mixed terpenoid compounds

[0056] Using NMR ( 1 H. 13 C, HSQC, COSY, HMBC, NOESY), HRESIMS, experimental ECD data and quantum chemical calculation ECD data and other physical and chemical data to determine the relative and absolute configuration of new structure compounds.

[0057] Compound 1 is a white powder. According to the positive high-resolution mass spectrum (m / z 495.2342, [M+Na] + ,calcd forC 27 H 36 O7 + ,495.2353) and negative high-resolution mass spectra (m / z 471.2380,[MH] - ,calcd for C 27 H 35 O7 - ,471.2377) determined that the molecular formula of compound 1 is C 27 H 36O7, unsaturation is 10. 1 H NMR (Table 1) combined with HSQC spectra revealed six methyl signals (H3-12, H3-13, H3-14, H3-15, H3-9′, H3-10′), one acetoxy signal (6-OAc), four methylene signals (H2-1, H2-2, H2-7, H2-11), two methine hydrogen signals (H-5, H-9), two oxygenated methine hydrogen signals (H-6, H-5′) and one olefinic hydrogen signal (H2-1′). 13 C NMR showed 27 carbon resonance signals, including 6 methyl groups, 4 methylene groups, 4 methine groups, 1 acetyl group, 1 methylene group, and 11 non-protonated carbons. The above NMR data showed the presence of a CC double bond and four carbonyl groups, occupying 5 unsaturations, indicating that compound 1 is a five-ring molecular skeleton structure. 1 H- 1 The HCOSY spectrum showed that H2-1 and H2-2 were correlated, and the HMBC spectrum showed that H2-2 to C-3 and H3-14 and H3-15 to C-3, C-4 and C-5 showed HMBC correlation, which confirmed that ring A ( Figure 1 ). COSY correlations of H-5, H-6 and H2-7, COSY correlations of H-9 and H2-11, H-6 to C-10 and C-8, H3-13 to C-5, C-10 and C-9, H3-12 to C-7, C-8, C-9 and C-7′, H3-9′ to C-3′, C-11 and C-2′, H2-1′ to C-3′, C-2′ and C-7′ deduced the decalin moiety (B and C). HMBC correlations of H3-9′ to C-3′ and C-4′; OH-6′ to C-6′, C-4′ and C-7′ proved the presence of a lactone bridge between C-3′ and C-7′ via C-4′ and C-6′. HMBC correlations of OH-6′ to C-6′, C-7′ and C-5′, H3-10′ to C-5′ and C-6′, and C-5′ (δ C 76.4), C-7′(δ C 68.8) and C-8′(δ C 68.8) downfield shifts indicate that the D ring is a 2-keto-5-methyloxirane moiety connected to the lactone bridge via C-6′ and C-7′. HMBC correlation of H-6 with OAc-6 and C-6 (δ C The low-field shift of 70.1) indicated that the acetyl group was connected to C-6, and the planar structure of compound 1 was finally determined.

[0058] According to the correlation between H3-15 and H-5, H-5 and H-9, H-9 and OH-6′, OH-6′ and H3-10′ in the NOESY spectrum, these protons are in the same plane, and the correlation between H3-14 and H3-13, H-6 and H3-13, H3-13 and H3-12, and H2-1′ and H-5 indicates that these protons are in opposite planes. The relative configuration of compound 1 is determined to be 5S*, 6R*, 8S*, 9S*, 10S*, 3′R*, 5′R*, 6′R*, 7′R*. The experimental ECD data of compound 1 are very similar to the quantum chemical calculation ECD data ( Figure 2 ), thus determining the absolute configuration of compound 1 to be 5S, 6R, 8S, 9S, 10S, 3′R, 5′R, 6′R, 7′R.

[0059] Compound 2 is a light pink powder. According to HRESIMS (m / z 429.2277[MH] - ), combined with NMR data, the molecular formula of compound 2 was determined to be C 25 H 34 O6, unsaturation is 9. 1 H NMR (Table 1) and HSQC spectra indicate six methyl signals (H3-12, H3-13, H3-14, H3-1′, H3-9′, H3-10′), one methoxy signal (8′-OMe), four methylene signals (H2-1, H2-2, H2-6, H2-7), one methine hydrogen signal (H-5), one oxygen-containing methine hydrogen signal (H-3), and one olefinic hydrogen signal (H-11). 13 C NMR shows 25 carbon signals, including six methyl groups, four methylene groups, three methine groups, one methoxy group, and eleven non-protonated carbons. The above NMR data indicate the presence of two CC double bonds and three carbonyl groups occupying five degrees of unsaturation, confirming that compound 2 is a tetracyclic molecular skeleton structure. According to HMBC and 1 H- 1 The COSY correlations of H2-2 to H2-1, H-3, and OH-3 in the H COSY spectrum, the HMBC correlations of H2-2 to C-4 and C-10, H2-1 to C-3 and C-5, and H3-13 and H3-14 to C-3, C-4, and C-5 in the H COSY spectrum were used to construct ring A ( Figure 3). The structure of ring B was constructed by COSY correlation from H2-6 to H-5 and H2-7, H2-6 to C-8 and C-10, and H2-7 to C-5 and C-9, and ring A was connected via C-5 and C-10. The structure of ring C was constructed by HMBC correlation from H-11 to C-8, C-2′ and C-9′, H3-9′ to C-3′ and C-2′, H3-1′ to C-3′, C-2′ and C-7′, H3-12 to C-8, C-9 and C-7′, and ring B was connected via C-8 and C-9. HMBC correlations from H3-10′ to C-5′, C-6′ and C-4′, H3-1′ to C-4′, C-2′ and C-7′, and OH-5′ to C-5′, C-7′ and C-6′ identified the D ring as a 2,2-methylcyclopentanol-1,3-dione moiety connected to the C ring via C-2′ and C-7′. 13 C NMR C-7′(δ C The chemical shift of 68.8) was significantly shifted to the downfield, and it was inferred that the methyl formate (C-8′ and OMe-8′) structure was partially connected to C-7′, and the planar structure of compound 2 was finally identified.

[0060] According to the correlation between H-3 and H-5 and H-5 and H-7a in the NOESY spectrum, these protons are on the same side of the plane, and the correlation between H3-12 and H-7b, H3-12 and OMe-8′, OMe-8′ and H3-1′, and H3-1′ and H3-10′ indicates that these protons are on the opposite side, thus determining the relative configuration of compound 2 as 3R*, 5S*, 8S*, 2′R*, 5′R*, 7′R*. The absolute configuration was determined by combining the quantum chemical calculation ECD data, and it was found that the measured ECD spectrum was very consistent with the quantum chemical calculation spectrum (3R, 5S, 8S, 2′R, 5′R, 7′R)-2 ( Figure 4 ), thus determining the absolute configuration of compound 2 to be 3R, 5S, 8S, 2′R, 5′R, 7′R.

[0061] The hydrogen and carbon NMR data of the above two new structure compounds are shown in Table 1

[0062] Table 1 Compounds 1 and 2 1 H(600MHz) and 13 C (150 MHz) NMR data (DMSO-d6)

[0063]

[0064]

[0065] Example 2: Evaluation of the anti-novel coronavirus pseudovirus activity of DMOA-derived mixed terpenoid compounds

[0066] The SARS-CoV-2 trVLP pseudovirus-infected A549-ACE2 cell model was used to evaluate the inhibitory effect of mixed terpenoid compounds on the new coronavirus. The reporter gene Nanoluc was inserted into it, and the Lucifer value was measured to indicate the level of viral replication. First, test whether the compound is toxic to A549-ACE2 cells. The specific steps are as follows:

[0067] (1) Cytotoxicity test of compounds on A549-ACE2 cells

[0068] a) A549-ACE2 cells were plated in 96-well plates in advance, and the cell density was about 70% to 80% after culturing for 20 hours;

[0069] b) Compounds were diluted 3-fold starting from 200 μM in DMEM medium containing 2% FBS (two replicate wells for each concentration);

[0070] c) Discard the original culture medium, add 100 μL of culture medium containing the diluted compound to the cells, and continue culturing for 24 h;

[0071] d) Remove the culture supernatant. Add 80 μL CellTiter-Lumi TM Steady buffer (Biyuntian CellTiter-Lumi TM Steady Luminescent Cell Viability Assay Kit). Horizontal shaking for 2 minutes, incubate at room temperature in the dark for 10 minutes;

[0072] e) Transfer to an opaque white plate, measure the Lucifer value, analyze the data, and find that both compounds are non-cytotoxic and suitable for further antiviral IC 50 Activity evaluation.

[0073] (2) Evaluation of the activity of compounds 1 and 2 against SARS-CoV-2 trVLP pseudovirus

[0074] a) A549-ACE2 cells were plated in 96-well plates in advance, and the cell density was about 90% after 24 hours of culture;

[0075] b) Compounds were diluted 3-fold starting from 200 μM in DMEM medium containing 2% FBS (two replicate wells for each concentration);

[0076] c) Discard the original culture medium and add 100 μL of culture medium containing the diluted compound to the cells for pretreatment for 1 hour;

[0077] d) Dilute the SARS-CoV-2 trVLP pseudovirus with 2% FSB DMEM at a ratio of 1:9, and add 40 μL of the virus dilution solution directly to each well, at which point the MOI is 0.1;

[0078] e) After 24 h of infection, cells were fixed with PFA and immunofluorescence stained (SARS2 N protein and DAPI). High-content scanning was performed to count the infection rate of cells in each well, and the data were analyzed to obtain the IC values ​​of compounds 1 and 2. 50 22.37 and 18.12 μM respectively.

[0079] The activity evaluation results showed that the new structure mixed terpenoid compounds 1 and 2 both have significant anti-new coronavirus pseudovirus activity, and their IC 50 The results show that the concentrations of 22.37 and 18.12 μM, respectively, can be used for the development of antiviral drugs. Therefore, the present invention provides candidate compounds for the development of new coronavirus drugs and provides a scientific basis for the development and utilization of deep-sea microbial resources.

[0080] The method of the present invention has been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications described herein within the content, spirit and scope of the present invention to implement and apply the technology of the present invention. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.

Claims

1. A terpenoid compound having one of the following structures or its stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts, prodrugs or isotope labels:

2. A pharmaceutical composition comprising the terpenoid compound according to claim 1 and pharmaceutical excipients.

3. The pharmaceutical composition according to claim 2, characterized in that It also includes other effective ingredients; the other effective ingredients are traditional Chinese medicine ingredients and / or western medicine ingredients.

4. The pharmaceutical composition according to claim 3, characterized in that The western medicine ingredients include: at least one of apimod, R82913, DS-6930, ONO 5334, oseltamivir phosphate, tetrandrine, clofazimine, astemizole, recombinant human angiotensin-converting enzyme 2 or favipiravir and / or pharmaceutically acceptable salts thereof.

5. Use of the terpenoid compound according to claim 1 or the pharmaceutical composition according to any one of claims 2 to 4 in the preparation of a medicament for preventing or treating diseases related to novel coronavirus infection.

6. The use according to claim 5, characterized in that The new coronavirus is a SARS-CoV-2trVLP pseudovirus.

7. A method for preparing and extracting the terpenoid compound according to claim 1, comprising: (I) using an organic solvent to ultrasonically extract a fermentation product of the deep-sea fungus Penicillium pancosmium A6A to obtain an organic extract; the organic solvent is selected from one or more combinations of dichloromethane, ethyl acetate, n-butanol, acetone, and methanol; (II) separating the organic extract in step (I) by normal phase silica gel column chromatography, using a dichloromethane-methanol gradient elution system, first eluting with dichloromethane-methanol in a volume ratio of 1:0, then eluting with dichloromethane-methanol in a volume ratio of 1:1, and finally eluting with dichloromethane-methanol in a volume ratio of 0:1, each volume elution is 1 L, and three fractions Fr.1, Fr.2, and Fr.3 are obtained by combining; (III) the fraction Fr.2 obtained in step (II) is first separated by a normal phase silica gel column, and then separated by a reverse ODS column and high pressure liquid chromatography to prepare compound 1; (IV) The fraction Fr.3 obtained in step (II) is firstly separated by a reverse ODS column and then by a normal phase silica gel column and high pressure liquid chromatography to obtain compound 2.

8. The method according to claim 7, characterized in that The deep-sea fungus Penicillium pancosmium is Penicillium pancosmium A6A; preferably, Penicillium pancosmium A6A is a rice solid fermentation culture thereof.

9. The method according to claim 8, characterized in that The fermentation culture comprises: (1) Penicillium pancosmium A6A activated on the PDA plate was inoculated into the PDB liquid culture medium, and the Erlenmeyer flask was placed in a shaker for shaking culture to prepare the seed culture medium; (2) The seed culture solution in step (1) is expanded and inoculated into a rice culture medium, and placed in a 25° C. incubator for constant temperature static fermentation for 32 days.

Citation Information

Patent Citations

  • Marine-derived meroterpenoid compounds I and II, preparation method thereof, and application of marine-derived meroterpenoid compounds I and II in preparation of antitumor drugs

    CN111004251A